Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

Lung cancer is the leading cause of cancer-related mortality worldwide. Detectable driver
mutations have now changed the course of lung cancer treatment with the emergence of …

Simple Summary Lung cancer remains one of the most common and difficult cancers to
treat. However, excellent progress in identifying the genetic causes of lung cancers has …

Kinase fusions represent an important type of somatic alterations that promote oncogenesis
and serve as diagnostic markers in lung cancer. We aimed to identify the landscape of …

The development of targeted therapy in epidermal growth factor receptor (EGFR)-mutated
non-small cell lung cancer (NSCLC) patients has radically changed their clinical …

Background Despite significant benefits from targeted therapy in patients with driver
mutations, inevitable drug resistance usually occurred in non-small cell lung cancer …

Abstract The Epidermal Growth Factor Receptor (EGFR) has been targeted through the
development of selective tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAb) …

Background: For epidermal growth factor receptor-mutant (EGFR-mutant) advanced non-
small cell lung cancer (NSCLC) patients, EGFR-tyrosine inhibitors such as gefitinib, erlotinib …